1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 17, 137, 137, 2, 7, 236, 44 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 18, 20, 5, 1, 48 and 27 molecules, respectively.
Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Accent Therapeutics Inc, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acepodia Biotech Inc, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acrotech Biopharma LLC, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2020
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
List of Figures
- Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AB Science SA
- AbbVie Inc
- ABL Bio Inc
- Accent Therapeutics Inc
- Acepodia Biotech Inc
- Acrotech Biopharma LLC
- Actinium Pharmaceuticals Inc
- Adlai Nortye Biopharma Co Ltd
- Advanced BioDesign
- Advenchen Laboratories LLC
- Aeglea BioTherapeutics Inc
- Affichem SA
- Agenus Inc
- Agios Pharmaceuticals Inc
- AI Therapeutics
- Aileron Therapeutics Inc
- AIMM Therapeutics BV
- Aleta Biotherapeutics Inc
- Alfasigma SpA
- Allogene Therapeutics Inc
- Amgen Inc
- Amphivena Therapeutics Inc
- Amplia Therapeutics Ltd
- Angiocrine Bioscience Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- ANP Technologies Inc
- Antengene Corp
- Antisense Therapeutics Ltd
- AnyGen Co Ltd
- APIM Therapeutics AS
- Aprea Therapeutics AB
- AptaBio Therapeutics Inc
- Aptevo Therapeutics Inc
- Aptose Biosciences Inc
- Aravive Inc
- Arcellx Inc
- Argenx SE
- Arog Pharmaceuticals Inc
- Arrien Pharmaceuticals LLC
- Arvinas Inc
- Ascentage Pharma Group International
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Athenex Inc
- ATP Biopharm
- AUM Biosciences Pte Ltd
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Avidin Ltd
- AVROBIO Inc
- Avvinity Therapeutics Ltd
- Bantam Pharmaceutical LLC
- Bayer AG
- BCI Pharma SA
- Beam Therapeutics Inc
- Beijing Immunochina Medical Science & Technology Co Ltd
- Bellicum Pharmaceuticals Inc
- BerGenBio ASA
- Betta Pharmaceuticals Co Ltd
- Bio-Cancer Treatment International Ltd
- Bio-Path Holdings Inc
- Biokine Therapeutics Ltd
- BioLineRx Ltd
- BioMed Valley Discoveries Inc
- Bionomics Ltd
- BioSight Ltd
- BioTheryX Inc
- BioXcel Therapeutics Inc
- BiVictriX Therapeutics Ltd
- bluebird bio Inc
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- Boston Biomedical Inc
- BoYen Therapeutics Inc
- Bridge Medicines LLC
- Bristol-Myers Squibb Co
- Canqura Oncology AB
- Cardiff Oncology Inc
- Carrick Therapeutics UK Ltd
- Catalent Inc
- CellCentric Ltd
- Cellectis SA
- Cellerant Therapeutics Inc
- Cellipse SAS
- Cellular Biomedicine Group Inc
- Celularity Inc
- Celyad Oncology
- Centrose LLC
- Changzhou Qianhong Bio-Pharma Co Ltd
- CharlestonPharma LLC
- Checkpoint Therapeutics Inc
- Chimerix Inc
- Chongqing Precision Biotech Co Ltd
- Chordia Therapeutics Inc
- Chugai Pharmaceutical Co Ltd
- Clear Creek Bio Inc
- Cleave Therapeutics Inc
- CoImmune Inc
- Constellation Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CrystalGenomics Inc
- CSPC Pharmaceutical Group Ltd
- Cue Biopharma Inc
- Cullinan Oncology LLC
- CuronBiotech Inc
- Cyclacel Pharmaceuticals Inc
- Cytovia Inc
- Daiichi Sankyo Co Ltd
- Dalriada Therapeutics Inc
- DC Prime BV
- Deciphera Pharmaceuticals Inc
- Delta-Fly Pharma Inc
- Demuris Ltd
- Denovo Biopharma LLC
- DiNonA Inc
- Dong-A ST Co Ltd
- Eli Lilly and Co
- Emercell SAS
- Eminent Biosciences
- EntreChem SL
- Enzyme by Design Inc
- Epigene Therapeutics Inc
- Epizyme Inc
- Escend Pharmaceuticals Inc
- ExCellThera Inc
- Exonate Ltd
- Expression Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fimecs Inc
- Flavocure Biotech LLC
- Forma Therapeutics Inc
- Fujifilm Holdings Corp
- Gadeta BV
- Gamida Cell Ltd
- GC Pharma
- GEMoaB Monoclonals GmbH
- Genentech Inc
- Genmab AS
- Genosco Inc
- Genus Oncology LLC
- Geron Corp
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GlycoMimetics Inc
- Glycostem Therapeutics BV
- GO Therapeutics Inc
- Golden Biotechnology Corp
- GT Biopharma Inc
- H3 Biomedicine Inc
- Hanmi Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Inc Ltd
- HEC Pharm Co Ltd
- Hefei Cosource Pharmaceutical Inc
- Helocyte Biosciences Inc
- HemoGenyx LLC
- HemoGenyx Pharmaceuticals Plc
- HiFiBiO SAS
- HighPass Bio Inc
- Hillstream BioPharma Inc
- Hinova Pharmaceuticals Inc
- Hoverink Biotechnologies Inc
- HRAIN Biotechnology Co Ltd
- Hummingbird Bioscience Pte Ltd
- Hunan Siweikang Therapeutics Ltd
- Hutchison MediPharma Ltd
- Hybrigenics SA
- I-Mab Biopharma Co Ltd
- iCell Gene Therapeutics LLC
- IGF Oncology LLC
- IGM Biosciences Inc
- Imago BioSciences Inc
- ImCheck Therapeutics SAS
- Immune Onc Therapeutics Inc
- Immune System Key Ltd
- ImmunoGen Inc
- Immunomedics Inc
- Inatherys
- Incuron LLC
- Incysus Therapeutics Inc
- Incyte Corp
- Inflection Biosciences Ltd
- Inmune Bio Inc
- Innovation Pharmaceuticals Inc
- Intellia Therapeutics Inc
- Interprotein Corp
- Intra-Immusg Pvt Ltd
- Io Therapeutics Inc
- Iterion Therapeutics
- Jasper Therapeutics Inc
- Jazz Pharmaceuticals Plc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Aidea Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- JSK Therapeutics Inc
- Jubilant Therapeutics Inc
- Juno Therapeutics Inc
- Juventas Cell Therapy Ltd
- JW Pharmaceutical Corp
- Kainos Medicine Inc
- Kartos Therapeutics Inc
- Karyopharm Therapeutics Inc
- Keystone Nano Inc
- Kiadis Pharma NV
- KinaRx LLC
- KisoJi Biotechnology Inc
- Komipharm International Co Ltd
- Konruns Pharmaceutical Co Ltd
- Kura Oncology Inc
- Kurome Therapeutics Inc
- Kymera Therapeutics LLC
- Laekna Therapeutics Shanghai Co Ltd
- Lai Corporation Pty Ltd
- Lead Discovery Center GmbH
- Les Laboratoires Servier SAS
- Leukos Biotech SL
- Lineage Cell Therapeutics Inc
- Lumos Pharma Inc
- Mablink Bioscience
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Magenta Therapeutics Inc
- Mana Therapeutics Inc
- Marker Therapeutics Inc
- Mateon Therapeutics Inc
- Maxinovel Pharmaceuticals
- MedAbome Inc
- MediGene AG
- Medivir AB
- MEI Pharma Inc
- Merck & Co Inc
- Merck KGaA
- Merus NV
- Meryx Inc
- Millennium Pharmaceuticals Inc
- Minneamrita Therapeutics LLC
- Miragen Therapeutics Inc
- MiRx Pharmaceuticals LLC
- Molecular Templates Inc
- Molecules For Health Inc
- Moleculin Biotech LLC
- MolMed SpA
- Multitude therapeutics Inc
- Mustang Bio Inc
- MyeloRx LLC
- Nanjing Iaso Biotherapeutics Co Ltd
- Nanjing Legend Biotech Co Ltd
- Nanjing Sanhome Pharmaceutical Co Ltd
- Nanovalent Pharmaceuticals Inc
- NantKwest Inc
- Nemucore Medical Innovations Inc
- Newave Pharmaceutical Inc
- NexImmune Inc
- Nkarta Inc
- NMS Group SpA
- Nohla Therapeutics Inc
- Northlake International LLC
- Novartis AG
- OHM Oncology
- Omeros Corp
- Oncoceutics Inc
- Oncoheroes Biosciences Inc
- OncoImmune Inc
- Oncopeptides AB
- OncoTartis Inc
- OncoTherapy Science Inc
- Oncternal Therapeutics
- Ono Pharmaceutical Co Ltd
- Opsyon
- Orano Med LLC
- Orca Biosystems Inc
- Orsenix Holdings BV
- Oryzon Genomics SA
- Otsuka Holdings Co Ltd
- Oxford BioTherapeutics Ltd
- Oxstem Ltd
- Pacylex Pharmaceuticals Inc
- PentixaPharm GmbH
- Peptron Inc
- PersonGen Biomedicine Suzhou Co Ltd
- Petra Pharma Corp
- Pfizer Inc
- Pharma Mar SA
- Pharos I&BT Co Ltd
- Phebra Pty Ltd
- Phi Pharma SA
- Philogen SpA
- PhoreMost Ltd
- Picobella LLC
- Pimera Inc
- PiNK Biopharma Ltd
- Pinotbio Inc
- Pinteon Therapeutics Inc
- Plexxikon Inc
- PRISM Pharma Co Ltd
- Promutech Pharmaceuticals Inc
- Protheragen Inc
- Provectus Biopharmaceuticals Inc
- Provention Bio Inc
- PTC Therapeutics Inc
- PYCTX Ltd
- Qualigen Therapeutics Inc
- Qurient Co Ltd
- Race Oncology Ltd
- Rafael Pharmaceuticals Inc
- Rasna Therapeutics Inc
- Regenacy Pharmaceuticals LLC
- Rhizen Pharmaceuticals SA
- Rich Pharmaceuticals Inc
- Rubius Therapeutics Inc
- Ryvu Therapeutics SA
- Salarius Pharmaceuticals Inc
- Samumed LLC
- Sandhill Therapeutics Inc
- Sanofi
- Sapience Therapeutics Inc
- Sareum Holdings Plc
- Seattle Genetics Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- SFA Therapeutics LLC
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai icell Biotechnology Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- SignalChem Lifesciences Corp
- Sino Biopharmaceutical Ltd
- SiNOPSEE Therapeutics Pte Ltd
- SL Bigen Inc
- SMET Pharmaceutical Inc
- Solasia Pharma KK
- SpecificiT Pharma Inc
- Spectrum Pharmaceuticals Inc
- AIkido Pharma Inc
- SphingoGene Inc
- Stelexis Therapeutics LLC
- Storm Therapeutics Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Sunesis Pharmaceuticals Inc
- Surface Oncology Inc
- SuviCa Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Synactix Pharmaceuticals Inc
- Syndax Pharmaceuticals Inc
- SYNIMMUNE GmbH
- Tacitus Therapeutics Inc
- TaiGen Biotechnology Co Ltd
- Takara Bio Inc
- Takeda Pharmaceutical Co Ltd
- TC BioPharm Ltd
- TeamedOn International LLC
- Teva Pharmaceutical Industries Ltd
- TheraPharm Deutschland GmbH
- Tiziana Life Sciences Plc
- Tmunity Therapeutics Inc
- Toko Pharmaceutical Industries Co Ltd
- Tolero Pharmaceuticals Inc
- TOLREMO Therapeutics AG
- TOT Biopharm Co Ltd
- Treadwell Therapeutics Inc
- Trillium Therapeutics Inc
- Triphase Accelerator Corp
- UbiVac LLC
- Vertex Pharmaceuticals Inc
- Veru Inc
- Vessel Scientific LLC
- Vichem Chemie Research Ltd
- VioQuest Pharmaceuticals Inc (Inactive)
- Viralytics Pty Ltd
- VM Discovery Inc
- Vor BioPharma Inc
- Vyriad Inc
- Wugen Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- XEME BioPharma Inc
- Xencor Inc
- Y-Biologics Inc
- Y-mAbs Therapeutics Inc
- Yungjin Pharm Co Ltd
- Zenith Epigenetics Ltd
- Zentalis Pharmaceuticals LLC
- ZIOPHARM Oncology Inc
- Zovis Pharmaceuticals
